All News

1 October 2012

New Four- and Five-Year Survival Data for YERVOY (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)Antibodies

1 October 2012

AVEO Announces Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer; New Data Presented at ESMOAntibodies

1 October 2012

Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancerAntibodies

1 October 2012

Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancerAntibodies

28 September 2012

Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer PatientsAntibodies

28 September 2012

New Data Demonstrate STELARA (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients with Moderate to Severe Plaque PsoriasisAntibodies

28 September 2012

Lonza and Intellect Neurosciences Announces Intellect’s Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to LonzaAntibodies

28 September 2012

XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet’s UveitisAntibodies

27 September 2012

UCB announces top-line phase 2 results for olokizumab in rheumatoid arthritisAntibodies

27 September 2012

CSL drug candidate in diabetes research breakthroughAntibodies

27 September 2012

Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe plaque psoriasisAntibodies

25 September 2012

Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS for Post-Transplant Patients with Hodgkin LymphomaAntibodies

22 September 2012

U.S. FDA Approves EYLEA (aflibercept) Injection for the Treatment of Central Retinal Vein OcclusionAntibodies

21 September 2012

Roche’s Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancerAntibodies

21 September 2012

VEGF Trap-Eye (aflibercept ophthalmic injection) Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in EuropeAntibodies

21 September 2012

MorphoSys’s MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis PatientsAntibodies

21 September 2012

FDA Approves New Indication For Prolia (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For FractureAntibodies

21 September 2012

ABLYNX AND ITS PARTNER ADVANCE NANOBODY CANDIDATE ALX-0751 IN PRE-CLINICAL DEVELOPMENTAntibodies

19 September 2012

Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer’s PatientsAntibodies

19 September 2012

Janssen Submits Application To FDA Requesting Approval Of SIMPONI Intravenous Formulation For Treatment Of Moderately To Severely Active Rheumatoid ArthritisAntibodies

19 September 2012

Spectrum Pharmaceuticals Initiates Phase 3 Study of ZEVALIN in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form of Aggressive Non-Hodgkin’s LymphomaAntibodies

18 September 2012

Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter InfectionsAntibodies

18 September 2012

Merck Withdraws European Filing for Erbitux in NSCLCAntibodies

18 September 2012

Ablynx’s First Inhaled Nanobody Successfully Completes Phase I StudyAntibodies

17 September 2012

Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)Antibodies

15 September 2012

Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational AnthraxAntibodies

13 September 2012

Glenmark Pharmaceuticals Announces the Initiation of Phase II Study for GBR 500 for Ulcerative ColitisAntibodies

12 September 2012

KaloBios Initiates Phase 2 Study with KB003 Humaneered Monoclonal Antibody in Severe AsthmaAntibodies

11 September 2012

Arsanis Expands Its Anti-Infective Monoclonal Antibody Programs with Additional Grant Support from FFG and EUROSTARSAntibodies

11 September 2012

Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD73 Inhibitor Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics